About Intignus Biotech
Intignus Biotech is a Healthcare company based in Pune (India) founded in 2018 by Vaishnavi Kulkarni. Early diagnosis devices for pregnancy disorders are manufactured. Intignus Biotech has raised $288.89 thousand across 3 funding rounds from investors including Indian Institute of Technology Kanpur, Jitendra Tanna and Ravi Nigam. The company has 8 employees. Intignus Biotech was last valued at $1.13 million in February 2023. Its chief executive, as recorded, is Vaishnavi Kulkarni. Its Indian entity Intignus Biotech Private Limited reported revenue of ₹1.73 Cr. Intignus Biotech offers products and services including Preeclampsia Screening Test. Its focus areas include Life Sciences, Women Health, In Vitro Diagnostic Tests and Diversified.
Company details
Intignus Biotech was founded in 2018 and is based in Pune, India, within the biotechnology sector. In-vitro diagnostic devices for early detection of pregnancy-related conditions, including preeclampsia and premature labor, are produced. Prenatal genetic screening tests are offered to assess maternal and fetal health. Cell culture services are provided for research applications.
- Headquarters Pune, India
- Employees 8
- Founders Vaishnavi Kulkarni
- Stage Minicorn
- SectorsHealthcare
- Email••••••••
- Website intignusbiotech.com
- Social LinkedIn Facebook Instagram
- Legal Name Intignus Biotech Private Limited
- Date of Incorporation 26 Jun, 2018
- Jurisdiction Pune, Maharashtra, India
- Annual Revenue₹1.73 Cr
FY 2026 · +175% YoY
- Net Loss-₹3.6 Lakh
FY 2026 · -2% margin
- EBITDA-₹1.6 Lakh
FY 2026 · -1% margin
- Total Equity Funding$288.89K (USD)
in 3 rounds
- Latest Funding Round$248.2K (USD), Seed
Feb 2023
- Investors
- Employee Count8
Associated legal entities of Intignus Biotech
Intignus Biotech operates through Intignus Biotech Private Limited (active). Its filings, financials, charges and directors are on the company page.
| Legal entity | Status | Incorporated | Registered in | Revenue (FY 2026) | Employees | Directors | Company page |
|---|---|---|---|---|---|---|---|
| Intignus Biotech Private Limited CIN U74999PN2018PTC177401 | Active | 26 Jun 2018 | Pune, Maharashtra | ₹1.7 Cr | 3 | View details |
Products & Services of Intignus Biotech
Intignus Biotech offers a comprehensive portfolio of products and services, including Preeclampsia Screening Test.
Test for early detection of preeclampsia in pregnant women.
Funding Insights of Intignus Biotech
Intignus Biotech has successfully raised a total of $288.89K across 3 strategic funding rounds. The most recent funding activity was a Seed round of $248.2 thousand completed in February 2023. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $288,887
- Total Rounds 3
- Last Round Seed — $248,200
- First Round $21,503
(Jun 2019)
- Investors Count 6
All 3 funding rounds of Intignus Biotech with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Feb 2023 | $248,200 | Seed | $1.13M | Venture Center | |
| Feb 2021 | $19,184 | Seed | $864,100 | – | |
| Jun 2019 | $21,503 | Seed | $••••• | Indian Institute of Technology Kanpur | – |
| Date | Valuation | Stage |
|---|---|---|
| Feb 2023 | $1.13M | •••••••• |
Last known valuation $1.13M (Feb 2023). 6 investors in total: 3 institutional and 3 angel.
Investors in Intignus Biotech
Intignus Biotech has secured backing from 6 investors, including angel, institutional, and venture fund investors. Prominent investors backing the company include Indian Institute of Technology Kanpur, Jitendra Tanna and Ravi Nigam.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Startups are incubated at Venture Center, backed by CSIR. | venturecenter.co.in | Pune, India | ||
Support is extended to innovators and entrepreneurs by the foundation. | ief-fie.ca | Ottawa, Canada | ||
Multiple engineering courses and degrees are offered at the institute. | 1959 | iitk.ac.in | Kanpur, India | |
JT Jitendra Tanna | Angel investor and entrepreneur, co-founder of EnKash, focused on fintech innovation. | unknown_ef19a949b3c14a16b | ||
RN Ravi Nigam | unknown_6ce15c006bce4b2e9 | |||
VG Vivek Gupta | Co-founder of Licious, active angel investor in Indian startups | unknown_975a4982acbe4d65b |
Investor details for Intignus Biotech
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Board of directors of Intignus Biotech Private Limited (Intignus Biotech)
Intignus Biotech Private Limited is the primary company behind Intignus Biotech. The board of Intignus Biotech Private Limited currently have 3 directors; the longest-serving is Vaishnavi Mohan Kulkarni, appointed in 2018. 3 earlier directors have ceased.
| Director | Designation | Appointed | Tenure | Entity |
|---|---|---|---|---|
| Vaishnavi Mohan Kulkarni DIN 08166274 | Director | 26 Jun 2018 | 8 yrs 4 mo | Intignus Biotech Private Limited |
| Sanjay Anant Gupte DIN 00079310 | Director | 06 Jan 2021 | 5 yrs 10 mo | Intignus Biotech Private Limited |
| Nimisha Singh DIN 08564977 | Director | 29 Mar 2024 | 2 yrs 7 mo | Intignus Biotech Private Limited |
People of Intignus Biotech
1 people are tracked at Intignus Biotech (1 in leadership); the tracked headcount is 8.
| Name | Role | Group |
|---|---|---|
| Co-Founder & CEO | Leadership |
Complete people profiles for Intignus Biotech
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Financials of Intignus Biotech
Figures of Intignus Biotech Private Limited, the primary company behind Intignus Biotech, for FY 2026. Revenue was ₹1.73 Cr (+175% year on year). Net loss was -₹3.6 Lakh (-2% margin). EBITDA was -₹1.6 Lakh (-1% margin). Revenue has grown at a compounded annual rate of +104% over three years and +57% over five years.
- ₹1.73 CrRevenue · FY 2026 · +175% YoY
- -₹3.6 LakhNet loss · -2% margin
- -₹1.6 LakhEBITDA · -1% margin
- ₹1.3 LakhPaid-up capital
- +104%Revenue CAGR, 3 years
- +57%Revenue CAGR, 5 years
Balance sheet, profit and loss, cash flow and ratios of Intignus Biotech Private Limited are on its company page.
Detailed financial statements for Intignus Biotech
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Timeline of Intignus Biotech
4 dated milestones of Intignus Biotech across 5 years, from founding to its latest funding, stage changes and deals.
- Founded Intignus Biotech is founded.
- Funding First funding round of $22K.
- Funding Latest funding round, Seed, of $248K.
- Milestone Reaches Minicorn status.
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Intignus Biotech
Intignus Biotech was founded in 2018 and raised its 1st funding round 1 year after it was founded.
Intignus Biotech is headquartered in Pune, India. It is registered at Pune, Maharashtra, India.
Vaishnavi Kulkarni is the CEO of Intignus Biotech, as recorded in our data. They have also founded this company.
Intignus Biotech is a funded company, having raised a total of $288.89K across 3 funding rounds to date. The company's 1st funding round was a Seed of $21.5K, raised on Jun 2019.
Intignus Biotech has 8 employees.
The primary company behind Intignus Biotech, Intignus Biotech Private Limited, reported revenue of ₹1.73 Cr for FY 2026, up 175% year on year.
Intignus Biotech was founded in 2018 and is based in Pune, India, within the biotechnology sector. In-vitro diagnostic devices for early detection of pregnancy-related conditions, including preeclampsia and premature labor, are produced. Prenatal genetic screening tests are offered to assess maternal and fetal health. Cell culture services are provided for research applications.
Intignus Biotech offers Preeclampsia Screening Test.
Intignus Biotech has 6 investors. Key investors include Indian Institute of Technology Kanpur, Jitendra Tanna, Ravi Nigam, Vivek Gupta, and Innovators & Entrepreneurs Foundation.
The valuation of Intignus Biotech is $1.13M as of Feb 2023.
Intignus Biotech operates through Intignus Biotech Private Limited.
The legal entities of Intignus Biotech currently have 3 directors, including Sanjay Anant Gupte, Nimisha Singh, Vaishnavi Mohan Kulkarni.